# A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)

> **NCT01076400** · PHASE1,PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 7 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** adavosertib
- **DRUG:** Topotecan
- **DRUG:** Cisplatin
- **DRUG:** Placebo to adavosertib

## Key facts

- **NCT ID:** NCT01076400
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05-31
- **Primary completion:** 2011-06-13
- **Final completion:** 2011-06-13
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The sponsor permanently suspended new enrollment into the trial and discontinued the study; which was not related to any concerns over product safety.
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01076400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01076400, "A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT01076400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*